E-Book, Englisch, 258 Seiten, eBook
E-Book, Englisch, 258 Seiten, eBook
ISBN: 978-981-1581-79-3
Verlag: Springer Singapore
Format: PDF
Kopierschutz: Wasserzeichen (»Systemvoraussetzungen)
Zielgruppe
Research
Autoren/Hrsg.
Weitere Infos & Material
Chapter 1_
Epigenetic modifying enzymes
. -Chapter 2_
Epigenetic modifying enzymes implicated in cancer
. -Chapter 3_
Classification of histone deacetylases (HDACs)
. -Chapter 4_
Implications of 18 HDAC isoforms in therapeutically monotonous cancers
. –Chapter 5_
Possible Mechanisms of HDACs in Cancer development.-
Chapter 6_
Different strategies employed for circumventing cancer resistance (chemo and radio) and mitigating toxicity.
-Chapter 7_
Limitations of conventional therapeutic regimens in treating cancer. -
Chapter 8
_Overview of epidrugs with special emphasis on HDAC inhibitors (HDACi).-
Chapter 9
_HDAC inhibitors as promising epidrugs for treating cancer. -
Chapter 10_
HDAC inhibitors in anticancer monotherapy
. -Chapter 11_
Distinct groups of histone deacetylase inhibitors (HDACi) based on the structural distinction, HDACs targeted. -
Chapter 12_
Limited efficacy of HDAC inhibitor-based monotherapy. -
Chapter 13_
Resistance mechanisms generated by cancer cells against HDACi based monotherapy. -
Chapter 14_
Toxicity issue of HDAC inhibitor based monotherapy. -
Chapter 15_
Combinatorial therapeutic strategies of HDACi. -
Chapter 16_
Designing Selective HDACi using computational and medicinal chemistry approach. -
Chapter 17.
Current therapeutic challenges and future directions.